<DOC>
	<DOC>NCT01446250</DOC>
	<brief_summary>This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received treatment for their chronic hepatitis C (HCV) genotype 1 infection.</brief_summary>
	<brief_title>Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criteria: Chronic HCV genotype 1 infection No previous treatment for HCV infection African American ethnicity Serum HCV RNA ≥ 1000 IU/ml, assessed by quantitative polymerase chain reaction or equivalent at screening visit, no upper limit A liver biopsy within 3 years prior to baseline Exclusion criteria: HCV genotype different from genotype 1 or coinfection with other HCV genotype Coinfection with Hepatitis B or HIV Any other cause of relevant liver disease other than HCV Presence or history of hepatic decompensation Alanine aminotransferase (ALT) ≥ 10 times ULN, more than 1 episode of elevated bilirubin (&gt; ULN) in past 6 months Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>